Hormone replacement therapy and stroke

Current Vascular Pharmacology

Volumn 6, Issue 2, 2008, Pages 112-123

  Billeci, Antonia M R ^a   Paciaroni, Maurizio ^a   Caso, Valeria ^a   Agnelli, Giancarlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Clinical trials; Hormone replacement therapy; Menopause; Risk; Stroke

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESCLIM; ESTRADIOL; ESTRAGEL; ESTROGEN; ESTROGEN DERIVATIVE; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PIPERAZINE ESTRONE SULFATE; PLACEBO; PROGESTERONE; SYNTHETIC CONJUGATED ESTROGEN; TIBOLONE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIAL WALL THICKNESS; BREAKTHROUGH BLEEDING; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG WITHDRAWAL; ESTROGEN BLOOD LEVEL; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERPLASIA; INSULIN RELEASE; INSULIN SENSITIVITY; LOW DRUG DOSE; MASTALGIA; MENOPAUSAL SYNDROME; MONOTHERAPY; MORTALITY; NEUROPROTECTION; NONHUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; TRANSDERMAL PATCH; TREATMENT INDICATION; VAGINA RING; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH; ESTROGEN THERAPY; FEMALE; MALE; RISK;

CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION ROUTES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MALE; POSTMENOPAUSE; RISK; SEX FACTORS; STROKE; WOMEN'S HEALTH;

EID: 47249111305     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016108783955338     Document Type: Review

References (154)

1. American Heart Association. 2000 Heart and Stroke statistical Update. Dallas, TX: American Heart Association, 1999.
2. Brown RD Jr, Whisnant JP, Sicks JRD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival. Secular trends in Rochester, Minnesota, through 1989. Stroke 1996; 27: 373-80.
3. Hurn PD, Brass LM. Estrogen and stroke: a balanced analysis. Stroke 2003; 34: 338-341.
4. Glader EL, Stegmayr B, Norrwing B, Terent A, Hulter-Asberg K, Wester PO, et al. Sex differences in management and outcome after stroke. A Swedish national perspective. Stroke 2003; 34: 1970-5.
5. Di Carlo A, Lamassa M, Baldreschi M, Pracucci G, Basile AM, Wolfe CD, et al. Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe. Data from a Multicenter Multinational Hospital-Based Registry. Stroke 2003; 34: 1114-9.
6. Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342-4.
7. Wolf PA, D'Agostinn RB, Balanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22. 312-8.
8. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36: 1115-9.
9. James A, Bushnell CD, Jamison M, Myers E. Incidence and risk factors for stroke in pregnancy and the purperium. Obstet Gynecol 2005; 106: 509-16.
10. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptive. A meta-analysis. JAMA 2000; 284: 72-8.
11. Chan WS, Ray J, Wai EK, Ginsburg S, Hannah ME, Corey PN, et al. Risk of stroke in women exposed to low-dose oral contraceptives. A critical evaluation of the evidence. Arch Intern Med 2004; 164: 741-7.
12. Fillit HM. The role of hormone replacement therapy in the prevention of Alzheimer's disease. Arch Intern Med 2002; 162: 1934-42.
13. Genazzani AR, Gambacciani M. Hormone replacement therapy. the perspective for the 21st century. Maturitas 1999; 32: 11-7.
14. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by post-menopausal women in the United States. Ann Intern Med 1999; 130: 545-53.
15. Wenger NK, Speroff L, Packard B. Cardiovascular Health and Disease in Women. N Engl J Med 1993; 329: 247-56.
16. Leys D. Ischemic strokes in young adults. Rev Med Interne 2003; 24: 585-93.
17. Littleton-Keamey MT, Klaus JA, Hum PD. Effects of combined oral conjugated estrogens and medroxyprogesterone acetate on brain infarction size after experimental stroke in rat. J Cereb Blood Flow Metab 2005; 25: 421-6.
18. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. Estrogen replacement after ischemic stroke: Report of the Women's Estrogen for Stroke Trial (WEST). N Engl J Med 2002; 345: 1243-9.
19. Falkeborn M, Persson I, Terènt A, Adami H-O, Lithell H, Bergstróm R. Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden. Arch Intern Med 1993; 153: 1201-9.
20. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility, 6th ed. Baltimore: Lippincott Williams & Williams, 1999.
21. Ettinger B. Overview of estrogen replacement therapy: a historical perspective. Proc Soc Exp Biol Med 1998; 217: 2-5.
22. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995; 35 (Suppl): 18S-24S.
23. Stumpf PG. Pharmacokinetics of estrogen. Obstet Gynecol 1990; 75(Suppl): 9S-14S.
24. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171-97.
25. Lobo RA. Absorption and metabolic effects of different types of estrogens and progestogens. Obstet Gynecol Clin North Am 1987; 14: 143-67.
26. Lyttle CR, Dey M. Estrogen complexes contained in conjugated equine estrogens (CEE): an overview of their structure and possible effects on target tissue. In: Paoletti R et al., editors. Women's health and menopause. Netherlands: Kluwer Academic Publishers, 1999: 169.
27. Ziel HK, Finkle WD. Increased risk of endometrial cancer among users of conjugated estrogens. N Eng J Med 1975; 293: 1167-70.
28. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet Gynecol 1993; 81: 265-71.
29. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Eng J Med 1985; 313: 969-72.
30. Rose PG. Endometrial-carcinoma. N Eng J Med 1996; 335: 640-9.
31. Whitehead MI, Frillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990; 75: S59-76.
32. Varma TR. Effect of long-term therapy with estrogen and progesterone on the endometrium of postmenopausal women. Acta Obstet Gynecol Scand 1985; 64:41-6.
33. Whitehead M, Lobo RA. Consensus conference: progestagen use in postmenopausal women. Lancet 1988; 2: 1243-4.
34. Marcia L, Stefanick. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005; 118: 64S-73S.
35. Smith CL, O'Malley BW. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004; 25: 45-71.
36. Kenemans P, Speroff L. Tibolone: Clinical recommendations and practical guidelines: A report of the International Tibolone Consensus Group. Maturitas 2005; 51: 21-28.
37. Palacios S. Tibolone: A tissue-specific approach to the menopause. Eur Heart J Supplements 2001; 3(Suppl M): M12-M16.
38. Utian WH, Gass MLS, Sullivan JM, et al. A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: consensus opinion of the North American menopause society. Menopause 2000; 7: 76-86.
39. Barrett-Connor E. An epidemiologist looks at hormones and heart disease in women. J Clin Endocrinol Metab 2003; 88: 4031-42.
40. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemostas 1992; 68: 392-5.
41. Nabulsi AA, Folsom AR, White A, Patschr W, Heiss G, Wu KK, et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-75.
42. The Writing Group for the PEPI Trial. Effects of estrogen or progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Am Med Assoc 1995; 273: 199-208.
43. Petitti D. Hormone replacement therapy for prevention. JAMA 2002; 288: 99-101.
44. Fletcher S, Colditz G. Failure of estrogen plus progestin therapy for prevention. JAMA 2002; 288: 366-8.
45. De Lignieres B, Mauvais-Jarvis P. Postmenopausal hormonal therapy. In: Scholler R, editor. Ovarian endocrinology. Paris: SEPE; 1976. p. 578-92.
46. Holst J, Cajander S, Carlstrom K, Damber MG, von Schoultz B. A comparison of liver protein induction in postmenopausal women during oral and percutaneous oestrogen replacement therapy. Br J Obstet Gynaecol 1983; 90: 355-60.
47. De Lignieres B. The case for a non-plasma lipoprotein etiology of reduced vascular risk in estrogen replacement therapy. Curr Opin Obstet Gynecol 1993; 5: 389-95.
48. De Lignieres B, Basdevant A, Thomas G, Thalabard JC, MercierBodard C, Conard J, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral vs. transdermal administration. J Clin Endocrinol Metab 1986; 62: 536-41.
49. Moorjani S, Dupont A, Labrie F, De Lignieres B, Cusan L, Dupont P, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral vesrsus transdermal administration of estrogens. J Clin Endocrinol Metab 1991; 73: 373-9.
50. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. Arterioscler Thromb Vasc Biol 1997; 17: 3071-8.
51. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75: 898-915
52. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Different effects of oral conjugated equine strogen and transdermal estrogen replacement on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2002; 106: 1771-6.
53. Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996; 94: 727-33.
54. Kim-Schulze S, McGowan K, Hubchak SC, Cid MC, Martin MB, Kleinman HK, et al. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 1996; 94: 1402-7.
55. Alvarez RJ, Gips SJ, Moldovan N, Wilhide CC, Milliken EE, Hoang AT, et al. 17b-estradiol inhibits apoptosis of endothelial cells. Biochem Biophys Res Commun 1997; 237: 372-81.
56. Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, et al. Estrogenmediated, endothelial nitric oxide synthasedependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 2003; 108: 3115-21.
57. Simoncini T, Genazzani AR. Direct vascular effects of estrogens and selective estrogen receptor modulators. Curr Opin Obstet Gynecol 2000; 12: 181-7.
58. Simoncini T, Hafezi-Moghadam A, Brazil D, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407: 538-41.
59. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003; 148: 281-92.
60. Vazquez F, Rodriguez-Manzanesque JC, Lydon JP, et al. Progesterone regulates proliferation of endothelial cells. J Biol Chem 1999; 274: 2185-92.
61. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects or conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 217-21.
62. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997; 3: 324-7.
63. Cheng W, Lau OD, Abumrad NA. Two antiatherogenic effects of progesterone on human macrophages; inhibition of cholesteryl ester synthesis and block of its enhancement by glucocorticoids. J Clin Endocrinol Metab 1999; 84: 265-71.
64. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kishimoto T, et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 243-8.
65. Xing D, Miller A, Novak L, Rocha R, Chen YF, Oparil S. Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 2004; 109: 234-41.
66. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani AR. In vitro effects of progesterone and progestins on vascular cells. Steroids 2003; 68: 831-6.
67. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-25.
68. Decensi A, Omodei U, Robertson C, Bonnani B, GuerrieriGonzaga A, Ramazzotto F, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoidplacebo trial in healthy women. Circulation 2002; 106: 1224-8.
69. Modena MG, Bursi F, Fantini G, Cagnacci A, Carbonieri A, Fortuna A, et al. Effects of hormone replacement therapy on Creactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. Am J Med 2002; 113: 331-4.
70. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal, I. Differential effects of oral vs. transdermal estrogen replacement therapy on Creactive protein in postmenopausal women. J Am Coll Cardiol 2003; 41: 1358-63
71. Clarke SC, Kelleher J, Lloyd-Jones, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynecol 2002; 109: 1056-62.
72. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003; 348: 645-50.
73. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
74. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy (HERS II). JAMA 2002; 288: 49-57.
75. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy results of the randomized, double-blind, placebocontrolled estrogen in venous thromboembolism trial. Thromb Haemost 2000; 84: 961-7.
76. Hoibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism: results from a randomized, double-blind, clinical trial. Thromb Haemost 2001; 85: 775-81.
77. Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32.
78. Conard J, Samama M, Basdevant A, Guy-Grand B, de Lignieres B. Differential AT III response to oral and parenteral administration of 17-beta estradiol. Thromb Haemost 1983; 49: 252.
79. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
80. Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, et al. Activated protein C resistance determined with a thrombin generationbased test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-70.
81. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-40.
82. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebocontrolled trial. Br J Haematol 2001; 115: 415-20.
83. Post MS, Christella M, Thomassen LG, van der Mooren MJ, van Baal WM, Rosing J, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in post-menopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116-21.
84. Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, et al. Differential effects of oral and transdermal estrogen/ progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomised trial. Arterioscler Thromb Vasc Biol 2003; 23: 1671-6.
85. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
86. Hulley S, FurbergC, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 58-66.
87. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942-4.
88. Rossouw JE. Hormones for coronary disease-full circle. Lancet 2002; 360: 1996-7.
89. Kuller LH. Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative. Arterioscler Thromb Vasc Biol 2003; 23: 11-6.
90. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-34.
91. Shlipak MG, Chaput LA, Vittinghoff E, Lin F, Bittner V, Knopp RH, et al.; Heart and Estrogen/progestin Replacement Study Investigators. Lipid changes on hormone therapy and coronary heart disease events in the heart and estrogen/progestin replacement study (HERS). Am Heart J 2003; 146: 870-5.
92. De Lignieres B, de Vathaire F, Le MG, Kuttenn F. Traitements hormonaux substitutifs de la menopause et risque cardiovasculaire: les specificites francaises.Mt-Med Ther 2003; 9: 38-45.
93. Sykes DH, Arveiler D, Salters CP, Ferrieres J, McCrum E, Amouvel P, et al. Psychosocial risk factors for heart disease in France and Northern Ireland: the prospective epidemiological study of myocardial infarction (PRIME) trial. Int J Epidemiol 2002; 31: 1094-7.
94. Skouby SO. Health in the menopause: advances in management. International Congress Series 1266 (2004) 151-155.
95. Kos-Kudła B, Staszewicz P. Katedra Patofizjologii i Endokrynologii, Klinika Endokrynologii w Zabrzu, S1. Akademia Medyczna w Katowicach. The role of hormone replacement therapy in the treatment of women with complicated chronic renal failure. Pol Merkur Lekarski 2003; 14: 163-7.
96. Ginsburg ES, Owen WF, Jr. Greenberg LM, Shea BF, Lazarus JM, Walsh BW. Estrogen absorption and metabolism in postmenopausal women with end-stage renal disease. J Clin Endocr Metab 1996; 81: 4414-17.
97. van Kammen E, Thijssen JH, Donker GH, Schwarz F. The excretion of metabolites of testosterone and of estradiol in male patients with chronic renal failure. Steroids 1975; 26: 508-515.
98. Anderson GD, Odegard PS. Pharmacokinetics of estrogen and progesterone in chronic kidney disease. Adv Chronic Kidney Dis 2004; 11: 357-360.
99. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause 2003; 10: 6-12.
100. Alkayed N, Murphy S, Traystman R, Hurn P, Miller V. Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke 2000; 31: 161-8.
101. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J Neurochem 1996; 66: 1836-44.
102. Brinton RD, Tran J, Proffitt P, Montoya M. 17 β-Estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem Res 1997; 22: 1339-51.
103. Foy MR, Henderson VW, Berger TW, Thompson RF. Estrogen and neural plasticity. Curr Direct Psychol Sci 2000; 9: 148-52.
104. Ohkura T, Teshima Y, Isse K, Matsuda H, Inoue T, Sakai Y, et al. Estrogen increases cerebral and cerebellar blood flows in postmenopausal women. Menopause 1995; 2: 13-8.
105. Bishop J, Simpkins JW. Estradiol enhances brain glucose update in ovariectomized rats. Brain Res Bull 1995; 36: 315-20.
106. Petanceska SS, Nagy G, Frail D, Gandy S. Ovariectomy and 17 β-estradiol modulate the levels of Alzheimer's amyloid β peptides in brain. Neurology 2000; 54: 2212-7.
107. Janowsky DS, Daris JM. Progesterone-estrogen effects on the uptake and release of norepinephrine by synaptosomes. Life Sci 1970; 9: 525-31.
108. Luine VN, McEwen BS. Effect of estradiol on turnover of type A monoamine oxidase in brain. J Neurochem 1977; 28: 1221-7.
109. Luine VN. 1975. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection area of female rats. Exp Neurol 1975; 89: 484-90.
110. Gibbs RB. Estrogen and nerve growth factor-related systems in brain. Ann NY Acad Sci 1994; 14: 165-99.
111. Woolley C, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during oestrus cycles in the rat. J Comp Neurol 1993; 336: 293-306.
112. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain implications for cognition and ageing. Neurology 1997; 48: S14-8.
113. Sarrel PM. Effects of ovarian steroids on the cardiovascular system. In The Circulation of the female from the Cradle to the Grave (ed. Ginsberg J.) Parthenon, Carnford, UK, 1989.
114. Sarrel PM. Ovarian hormones and the circulation. Maturitas 1990; 590: 287-98.
115. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. New Engl J Med 1999; 340: 1801-11.
116. O'Rourke ST, Vanhoutte PM, Miller VM. Vascular pharmacology. In: Creager MA, Dzau V, Loscalso J, eds. Vascular Medicine: A Companion to Braunwald's Heart Disease. Philadelphia, Pa: Elsevier; 2006: 71-100
117. Ridker PM, Cook NR, Lee I-M, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
118. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilatation in postmenopausal women. Ann Intern Med 1994; 121: 936-41.
119. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized control trial. JAMA 2003; 289: 2663-72.
120. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al.; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized control trial. JAMA 2003; 289: 2651-62.
121. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effect of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative Steering Committee. JAMA 2004; 291: 1701-12.
122. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999; 19: 893-9.
123. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288: 980-7.
124. Prestwood KM, Unson C, Kulldorff M, Cushman M. The effect of different dose of micronized 17-β estradiol on C-reactive protein, interleukin 6, and lipid in older women. J Gerontol A Biol Sci Med Sci 2004; 59: 827-32.
125. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effects of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999; 100: 717-22.
126. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22: 201-10.
127. Yang SH, Shi J, Day AL, Simpkins JW. Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke 2000; 31: 745-9, discussion 749-50.
128. McCullough LD, Alkayed NJ, Traystman RJ, Williams MJ, Hurn PD. Postischemic estrogen reduced hypoperfusion and secondary ischemia after experimental stroke. Stroke 2001; 32: 796-802.
129. Wise PM. Estrogens: protective or risk factors in brain function? Progress Neuro-Psychopharmacol Biol Psych 2003; 69: 181-91.
130. Wise PM. Impact of menopause on the brain. Alzheimer's Dis Assoc Disord 2003; 17:S48-50.
131. Schmidt R, Fazekas F, Reinhart B, Kapeller P, Fazekas G, Offenbacher H, et al. Estrogen replacement therapy in older women: a neuropsychological and brain MRI study. J Am Geriatr Soc 1996; 44: 1307-13.
132. Cook IA, Morgan ML, Dunkin JJ, David S, Witte E, Lufkin R, et al. Estrogen replacement therapy is associated with less progression of subclinical structural brain disease in normal elderly women: a pilot study. Intern J Geriatr Psych 2002; 17: 610-8.
133. Eberling JL, Wu C, Haan MN, Mungas D, Buonocore M, Jagust WJ. Preliminary evidence that estrogen protects against age-related hippocampal atrophy. Neurobiol Aging 2003; 24: 725-32.
134. Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, Hou Y, Fujita M, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psych 2003; 160: 1522-4.
135. Maki PM, Resnick SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging 2000; 21: 373-383.
136. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995; 38: 199-210.
137. Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR. Short-term predictors of incident of stroke in older adults. The Cardiovascular Health Study. Stroke 1996; 27: 1479-86.
138. Whisnant JP, Wiebers DO, O'Fallon WM, Sicks JD Frye RL. A population-based model of risk factors for ischemic stroke: Rochester, Minnesota. Neurology 1996;1420-8
139. Upmark E. Life and death without ovaries. Acta Med Scand 1962; 172: 129-35.
140. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. New Engl J Med 1985; 313: 1038-43.
141. Byrd BF Jr., Burch JC, Vaughn WK. The effects of long-term estrogen support after hysterectomy. A report of 1016 cases. Ann Surg 1977; 185: 574-80.
142. MacMahon B. Cardiovascular disease and non-contraceptive oestrogen therapy. In: Oliver MF, editor. Coronary Heart Disease in Young Women. New York: Churchill Livinstone, 1978: 197-207.
143. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990; 97: 1080-6.
144. Schairer C, Adami H-O, Hoover R, Persson I. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology 1997; 8: 59-65.
145. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-41.
146. Cairu L, Gunnar E, Bo Hedblad, Göran B, Lars J. Risk of stroke and hormone replacement therapy. A prospective cohort study. Maturitas 2006; 54: 11-18.
147. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al. Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen-Progestin Replacement Study (HERS). Circulation 2001; 103: 638-42.
148. Bushnell CD, Newby LK, Goldstein LB, Lin F, Yaffe K, Simon JA. Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS). Neurology 2004; 62: 968-70.
149. Bath PMW, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330: 342-5.
150. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al.; the Expert Panel/Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women. JACC 2007; 49: 1230-50.
151. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-77.
152. de Lecinana MA, Egido JA, Fernandez C, Martinez-Vila E, Santos S, Morales A, et al.; PIVE Study Investigators of the Stroke Project of the Spanish Cerebrovascular Diseases Study Group. Risk of ischemic stroke and lifetime estrogen exposure. Neurology 2007 2; 68: 33-8.
153. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM. Lipid levels and the risk of ischemic stroke in women. Neurology 2007; 68: 556-62.
154. Harmon S, Brinton E, Cedars M, Lobo RA, Manson JE, Merriam G, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climateric 2005; 8: 3-12